Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Forensic Leg Med ; 19(8): 497-8, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23084317

RESUMEN

OBJECTIVE: To report about a case of acute renal failure due to absence of communication between physician and patient. CASE SUMMARY: A 78 year old man with human immunodeficiency virus (HIV) accessed our hospital and was brought to our attention in August 2011 for severe renal failure. Clinical history revealed that he had been taking highly active antiretroviral therapy with lamivudine/abacavir and fosamprenavir since 2006. In April 2011 due to an augmentation in creatinine plasma levels, a reduction in lamivudine dosage to 100 mg/day and the prescription of abacavir 300 mg/day became necessary. Unfortunately, the patient took both lamivudine and abacavir therefore the association of the two medications (lamivudine/abacavir) lead to asthenia and acute renal failure within a few days. CONCLUSIONS: This case emphasizes the importance about how physicians must pay very careful attention during drug prescription, most particularly, as far as elderly patients are concerned. In fact, communication improvement between physicians and patients can prevent increase of adverse drug reactions related to drug dispensing, with consequential reduction of costs in the healthcare system.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Astenia/inducido químicamente , Didesoxinucleósidos/efectos adversos , Lamivudine/efectos adversos , Errores de Medicación , Anciano , Terapia Antirretroviral Altamente Activa/efectos adversos , Didesoxinucleósidos/administración & dosificación , Infecciones por VIH/tratamiento farmacológico , Humanos , Lamivudine/administración & dosificación , Masculino
2.
Infection ; 40(3): 299-302, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22173948

RESUMEN

PURPOSE: Universal anti-hepatitis B vaccination of infants and of 12-year-old children became mandatory in Italy in 1991. The purpose of this study was to evaluate the persistence of anti-hepatitis B surface (HBs) antibodies several years after a primary course of vaccination. METHODS: In 2010, anti-HBs titers were measured in all subjects aged between 5 and 25 years residing in a southern Italian town. Individuals with an anti-hepatitis B antibody concentration of 10 IU/ml or more were considered to be protected. RESULTS: Of the 671 subjects evaluated, 149 (30%) lacked protective antibodies. Fifty-three (29.4%) of the subjects had been vaccinated ≤10 years earlier and 96 (30.3%) more than 10 years earlier (P = not significant). Subjects vaccinated in infancy were more likely to lack protective anti-HBs antibodies than subjects vaccinated at 12 years of age, regardless of the years elapsed since immunization. CONCLUSIONS: Most subjects maintained protective antibodies for a considerable number of years after vaccination. Vaccination in adolescence results in more prolonged immunogenicity than vaccination in infancy.


Asunto(s)
Anticuerpos contra la Hepatitis B/sangre , Vacunas contra Hepatitis B/inmunología , Hepatitis B/inmunología , Adolescente , Adulto , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática , Femenino , Hepatitis B/prevención & control , Antígenos del Núcleo de la Hepatitis B/sangre , Antígenos del Núcleo de la Hepatitis B/inmunología , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos de Superficie de la Hepatitis B/inmunología , Vacunas contra Hepatitis B/administración & dosificación , Virus de la Hepatitis B/aislamiento & purificación , Humanos , Italia , Masculino , Factores de Tiempo , Adulto Joven
3.
Intervirology ; 51(6): 407-9, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-19258719

RESUMEN

OBJECTIVE: We report elevated serum alanine aminotransferase (ALT) levels during pegylated interferon (PEG-IFN)-alpha-2a in a patient with chronic HCV without other clinical manifestations. CASE SUMMARY: A 38-year-old man presented for HCV infection evaluation. Serum aspartate aminotransferase (AST) and ALT levels were 43 and 116 U/l, respectively; RT-PCR blood analysis revealed HCV-RNA infection. PEG-IFN-alpha-2b plus ribavirin treatment induced both a rapid virologic response and a normalization of transaminase plasma levels. During follow-up, an increase in transaminase and HCV-RNA values prompted us to start a new antiviral treatment with PEG-IFN-alpha-2a plus ribavirin. Four months later, after the follow-up, a new blood test documented both a HCV-RNA titer <50 U/ml and an increase in ALT and AST plasma levels. Immunostaining of the liver biopsy showed an accumulation of PEG-IFN-alpha-2a. PEG-IFN-alpha-2a elimination and the addition of recombinant IFN-alpha-2a induced normalization of the plasma transaminase levels in about 2 months. CONCLUSION: We postulate PEG-IFN-alpha-2a treatment because both the molecular weight and the distribution volume of the PEG-IFN may accumulate in the liver resulting in an increase of plasma transaminase levels. In contrast, during PEG-IFN-alpha-2b treatment, we did not document any increase in plasma transaminase values probably because of the lower molecular weight of the PEG.


Asunto(s)
Alanina Transaminasa/sangre , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/efectos adversos , Interferón-alfa/uso terapéutico , Polietilenglicoles/efectos adversos , Adulto , Antivirales/efectos adversos , Antivirales/farmacología , Antivirales/uso terapéutico , Aspartato Aminotransferasas/sangre , Quimioterapia Combinada , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Hepacivirus , Hepatitis C Crónica/enzimología , Humanos , Interferón alfa-2 , Interferón-alfa/farmacología , Hígado/efectos de los fármacos , Masculino , Polietilenglicoles/farmacología , Polietilenglicoles/uso terapéutico , Proteínas Recombinantes , Ribavirina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA